8IX3

Cryo-EM structure of SARS-CoV-2 BA.4/5 spike protein in complex with 1G11 (local refinement)

8IX3 の概要

• エントリーDOI: 10.2210/pdb8ix3/pdb
• EMDBエントリー: 35788
• 分子名称: light chain of 1G11, heavy chain of 1G11, BA.4/5 variant spike protein (3 entities in total)
• 機能のキーワード: sars-cov-2, neutralizing antibody, cryo-em, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 49351.15

構造登録者

Sun, H.,Jiang, Y.,Zheng, Z.,Zheng, Q.,Li, S. (登録日: 2023-03-31, 公開日: 2023-11-15, 最終更新日: 2024-11-20)

主引用文献

Sun, H.,Wang, Y.,Chen, X.,Jiang, Y.,Wang, S.,Huang, Y.,Liu, L.,Li, Y.,Lan, M.,Guo, H.,Yuan, Q.,Zhang, Y.,Li, T.,Yu, H.,Gu, Y.,Zhang, J.,Li, S.,Zheng, Z.,Zheng, Q.,Xia, N.
Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant.
J.Virol., 97:e0113723-e0113723, 2023

PubMed Abstract: The ongoing COVID-19 pandemic has been characterized by the emergence of new SARS-CoV-2 variants including the highly transmissible Omicron XBB sublineages, which have shown significant resistance to neutralizing antibodies (nAbs). This resistance has led to decreased vaccine effectiveness and therefore result in breakthrough infections and reinfections, which continuously threaten public health. To date, almost all available therapeutic nAbs, including those authorized under Emergency Use Authorization nAbs that were previously clinically useful against early strains, have recently been found to be ineffective against newly emerging variants. In this study, we provide a comprehensive structural basis about how the Class 3 nAbs, including 1G11 in this study and noted LY-CoV1404, are evaded by the newly emerged SARS-CoV-2 variants.

PubMed: 37855619
DOI: 10.1128/jvi.01137-23

実験手法

ELECTRON MICROSCOPY (3.98 Å)